Increased Serum Nesfatin-1 Levels in Patients with Impaired Glucose Tolerance

Abstract

65I In nc cr re ea as se ed d S Se er ru um m N Ne es sf fa at ti in n--1 1 L Le ev ve el ls s i in n P Pa at ti ie en nt ts s w wi it th h I Im mp pa ai ir re ed d G Gl lu uc co os se e T To ol le er ra an nc ce e B Bo oz zu ul lm mu uş ş G Gl lu uk ko oz z T To ol le er ra an ns sı ı O Ol la an nl la ar rd da a A Ar rt tm mı ış ş S Se er ru um m N Ne es sf fa at ti in n--1 1 D Dü üz ze ey yl le er ri i Purpose: Nesfatin-1 is a recently discovered energy-regulating peptide, widely expressed in both central and peripheral tissues. It is involved in various functions, such as the stimulation of hypothalamic-pituitary-adrenal axis and sympathetic nervous system, infl uencing visceral functions, water intake, and regulation of temperature and emotions. It exerts a direct glucose-dependent insulinotropic action on the beta cells of pancreatic islets. The current study evaluated nesfatin-1 levels and insulin response to glucose load in patients with impaired glucose tolerance (IGT) and in healthy subjects. Material and Method: Of those patients who underwent the oral glucose tolerance test (OGTT), 14 with IGT and 13 body mass index-(BMI) and age-matched healthy subjects as controls were included in the study. Blood samples were taken at 0, 60 and 120 min, and the glucose, insulin, and nesfatin-1 levels were measured. Results: The basal levels of glucose, insulin, and nesfatin-1 were significantly higher in the patients with IGT than in controls. Two-way repeated measures ANOVA revealed that change in time (CIT) for glucose and insulin during an OGTT was significant (p<0.001 and p<0.001, respectively). CIT for glucose and insulin was significantly different between the IGT patients and the controls (p<0.001 and p=0.003, respectively). CIT for nesfatin-1 was not significant (p=0.406) and did not differ significantly between the two groups (p=0.331). Discussion: The elevated levels of basal nesfatin-1 were observed in the patients with IGT. There was no change in the absolute nesfatin-1 levels in response to glucose load in either group. The increase in the levels of basal nesfatin-1 may refl ect a compensatory mechanism to regulate the impaired glucose metabolism in the IGT patients, which is later underwhelmed with the onset of diabetes.

Increased hip circumference in individuals with metabolic syndrome affects serum nesfatin-1 levels

“…In the present study, serum nesfatin-1 levels were lower in individuals diagnosed with metabolic syndrome. This result is similar to other studies investigating the metabolic syndrome and its components 21–24 26 27. In the present study, no significant difference was found between the BMI and body fat percentage of the case and control groups.…”

“…This result is similar to other studies investigating the metabolic syndrome and its components. 21–24 26 27 In the present study, no significant difference was found between the BMI and body fat percentage of the case and control groups. In this case, the decrease in the level of nesfatin-1 indicates that there is no weight or body fat percentage.…”

“…The comparison of the two groups in terms of their serum nesfatin-1 levels revealed that the mean serum nesfatin-1 levels were lower in those with metabolic syndrome than in those without metabolic syndrome. In another study investigating the serum nesfatin-1 levels in individuals with impaired glucose tolerance, the mean serum nesfatin-1 level was lower in the individuals with impaired glucose tolerance than in the individuals in the healthy control group 23. In a study conducted with patients with type 2 diabetes, plasma nesfatin-1 levels were decreased in patients with type 2 diabetes compared with healthy controls or patients with type 1 diabetes 24.…”

“…In another study investigating the serum nesfatin-1 levels in individuals with impaired glucose tolerance, the mean serum nesfatin-1 level was lower in the individuals with impaired glucose tolerance than in the individuals in the healthy control group. 23 In a study conducted with patients with type 2 diabetes, plasma nesfatin-1 levels were decreased in patients with type 2 diabetes compared with healthy controls or patients with type 1 diabetes. 24 In their study, Aslan et al 25 found that serum nesfatin-1 levels were lower in pregnant women with gestational diabetes mellitus than in healthy controls.…”

Nesfatin-1: An Anorexigenic Peptid

“…A modulation glucose metabolsm by peripheral rather than central nesfatin-1 . In a study by Akın et al (Akın et al, 2017), fasting plasma nesfatin-1 levels of patients with IGT were higher than the control group. The mean fasting nesfatin-1 levels of patients with IGT and control group were 2.1 ± 2.6 ng/mL, 0.5 ± 0.2 ng/mL, respectively (p=0.033).…”